Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal…

StudyOcular immunology and inflammation· Jul 2026

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Víctor Llorenç, Elisabetta Miserocchi, Cristina Fonseca, Uwe Pleyer

UveitisStudyTreatmentQ2IF 1.7

Fluocinolone acetonide implant associated with complete inflammation resolution in 92.9% of uveitis eyes

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Víctor Llorenç … Uwe Pleyer

Ocular immunology and inflammation · Jul 2026 · Q2 in Ophthalmology

Purpose

To evaluate the effectiveness and safety of the 0.19 mg fluocinolone acetonide (fluocinolone acetonide) intravitreal implant for the management of immune checkpoint inhibitor (immune checkpoint inhibitor)-associated uveitis.

Methods

Multicenter retrospective case-series including patients who developed uveitis during immune checkpoint inhibitor therapy and were treated with a 0.19 mg fluocinolone acetonide implant.

n = 9 patients

Results

92.9%

vision-threatening eye inflammation went away completely in nearly all treated eyes

n = 9 patients

More results

Median time from immune checkpoint inhibitor initiation to uveitis onset was 5.0 months (interquartile range [IQR]: 2.0-6.0).

Best-reported visual acuity improved significantly from uveitis onset (0.79 ± 0.17 logMAR) to last follow-up (0.19 ± 0.04 logMAR; p = 0.0008).

More results

Anterior chamber cell, flare, and vitreous haze resolved in all eyes ( p < 0.001 for all comparisons).

IOP remained stable, with one transient elevation successfully controlled with topical therapy.

“

Conclusion · 1 of 2

The 0.19 mg fluocinolone acetonide intravitreal implant provided sustained control of inflammation, significant visual improvement, and reduced treatment burden in patients with immune checkpoint inhibitor-associated uveitis.

Conclusion · 2 of 2

This local therapeutic approach may facilitate continuation of systemic immunotherapy while maintaining ocular disease control.

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Immune Checkpoint Inhibitor-Associated Uveitis Treated with the 0.19 Mg Fluocinolone Acetonide Intravitreal Implant: Clinical Outcomes in a Retrospective Case-Series.

Related papers